Arriva Pharma recaps with $6M for respiratory anti-inflammatory drugs
See our story on this Alameda, Calif., biotech in Friday’s daily briefing at VentureBeat Life Sciences.
Next Story: The Scrabulous Facebook game in the NYT spotlight
Previous Story: Science by press release — PrimeGen’s murky stem-cell “breakthrough”
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.